1,891 results on '"Cooper, Mark E"'
Search Results
202. Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
203. The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
204. ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
205. Therapeutic Interruption of Advanced Glycation in Diabetic Nephropathy: Do All Roads Lead to Rome?
206. Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study
207. Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway
208. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
209. Diabetic Vascular Injury and ACE: Potential for Pharmacological Prevention of Complications of Later Life
210. Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
211. Pathogenesis, prevention, and treatment of diabetic nephropathy
212. Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney
213. Is diabetic nephropathy disappearing from clinical practice?
214. Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes
215. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
216. Comparison of the Effects of Vitamins and/or Mineral Supplementation on Glomerular and Tubular Dysfunction in Type 2 Diabetes: Response to Farvid et al.
217. Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes
218. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney
219. Targets to retard the progression of diabetic nephropathy
220. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes
221. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes
222. Myocardial infarction increases ACE2 expression in rat and humans
223. Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes
224. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease
225. Anemia With Impaired Erythropoietin Response in Diabetic Patients
226. Can Advanced Glycation End Product Inhibitors Modulate More than One Pathway to Enhance Renoprotection in Diabetes?
227. Localization of the Ezrin Binding Epitope for Glycated Proteins
228. Low-Molecular Weight Advanced Glycation End Products: Markers of Tissue AGE Accumulation and More?
229. Effects of Advanced Glycation End Products on Ezrin-Dependent Functions in LLC-PK1 Proximal Tubule Cells
230. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
231. Limitations of cognitive status exams: a case based discussion
232. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin
233. ACE2, a new regulator of the renin–angiotensin system
234. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
235. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease
236. The Management of Diabetic Proteinuria: Which Antihypertensive Agent?
237. AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interaction
238. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes
239. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-α-Dependent Pathway
240. Interactions between Angiotensin II and NF-κB–Dependent Pathways in Modulating Macrophage Infiltration in Experimental Diabetic Nephropathy
241. Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products
242. Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
243. Improved Islet Morphology after Blockade of the Renin-Angiotensin System in the ZDF Rat
244. Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes: An Asian perspective from the RENAAL study
245. Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis
246. Connective Tissue Growth Factor Is Up-Regulated in the Diabetic Retina: Amelioration by Angiotensin-Converting Enzyme Inhibition
247. Heparanase Is Involved in the Pathogenesis of Proteinuria as a Result of Glomerulonephritis
248. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins
249. Increased Renal Vascular Endothelial Growth Factor and Angiopoietins by Angiotensin II Infusion Is Mediated by Both AT1 and AT2 Receptors
250. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.